BeiGene, Ltd. Business Operations Contracts & Agreements
11 Contracts & Agreements
- Collaboration Agreements (6 contracts)
- Indemnification Agreements (1)
- Termination Agreements (4)
- First Amendment to the Settlement and Termination Agreement, dated as of January 10, 2024, by and between the Registrant, BeiGene Switzerland GmbH, Bristol-Myers Squibb Company,... (Filed With SEC on February 26, 2024)
- Mutual Termination and Release Agreement, dated September 17, 2023, by and between BeiGene Switzerland GmbH and Novartis Pharma AG (Filed With SEC on November 9, 2023)
- Settlement and Termination Agreement, dated as of August 1, 2023, by and between the Registrant, BeiGene Switzerland GmbH, Bristol-Myers Squibb Company, Celgene Corporation,... (Filed With SEC on November 9, 2023)
- Mutual Termination and Release Agreement, dated July 10, 2023, by and between BeiGene Switzerland GmbH and Novartis Pharma AG (Filed With SEC on August 2, 2023)
- Second Amendment to Collaboration Agreement dated (Filed With SEC on May 4, 2023)
- First Amendment to Collaboration Agreement dated April 20, 2022, by and between the Registrant and Amgen Inc (Filed With SEC on August 8, 2022)
- Collaboration and License Agreement, dated January 11, 2021, by and between BeiGene Switzerland GmbH and Novartis Pharma AG (Filed With SEC on May 6, 2021)
- Collaboration Agreement, dated October 31, 2019, by and among the Registrant, BeiGene Switzerland GmbH and Amgen Inc (Filed With SEC on March 2, 2020)
- Letter Agreement, dated June 14, 2019, by and among the Registrant, BeiGene Switzerland GmbH, Celgene Corporation and Celgene Switzerland LLC, to terminate the Amended and... (Filed With SEC on August 8, 2019)
- Amended and Restated Exclusive License and Collaboration Agreement, dated August 31, 2017, by and among the Registrant, Celgene Corporation and Celgene Switzerland LLC (Filed With SEC on November 13, 2017)
- INDEMNIFICATION AGREEMENT (Filed With SEC on January 19, 2016)
